Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete demand for its goods and services. Write to Rob Curran at [email protected]

Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for a rare muscle disorder.

By Christy Santhosh and Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics slumped 36% in premarket trading on Monday after the company reported the death of a second patient in three months who had received its gene therapy,

Sarepta Therapeutics shares plunged 36% after the company reported a second case of acute liver failure resulting in death from taking Elevidys, which is a gene therapy for patients with Duchenne muscular dystrophy.